Arthritis Group Recent Clinical Trials

September, 2016 Gilead Services
Protocol: GS-US-417-0301
A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

September, 2016 Gilead Services
Protocol: GS-US-417-0302

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDS) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response to Biologic DMARDS(s) Treatment

April, 2017 CREDO 4 R-Pharm
Protocol: CL04041024

A Multicenter, Open-Label, Phase 3 Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis

April, 2017 Samumed
Protocol: SM04690-OA-04

A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

May, 2017 Gilead Services
Protocol: GS-US-417-0304

A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

November, 2017 Samumed
Protocol: SM04690-OA-05

A Phase 3, Multicenter, Observational Long-term Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects with Moderately to Severely Symptomatic Osteoarthritis

October, 2018 Celgene Corporation
Protocol: CC-10004-PSA-013

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) In Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS And /Or ≤ 1 Conventional Synthetic DMARD